JP2002512947A5 - - Google Patents

Download PDF

Info

Publication number
JP2002512947A5
JP2002512947A5 JP2000545506A JP2000545506A JP2002512947A5 JP 2002512947 A5 JP2002512947 A5 JP 2002512947A5 JP 2000545506 A JP2000545506 A JP 2000545506A JP 2000545506 A JP2000545506 A JP 2000545506A JP 2002512947 A5 JP2002512947 A5 JP 2002512947A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
fviii
colloidal particles
protein
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000545506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002512947A (ja
JP4545928B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL1999/000217 external-priority patent/WO1999055306A1/en
Publication of JP2002512947A publication Critical patent/JP2002512947A/ja
Publication of JP2002512947A5 publication Critical patent/JP2002512947A5/ja
Application granted granted Critical
Publication of JP4545928B2 publication Critical patent/JP4545928B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000545506A 1998-04-27 1999-04-23 第viii因子及び中性リポソームを含有する薬学的組成物 Expired - Fee Related JP4545928B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL124224 1998-04-27
IL12422498 1998-04-27
PCT/IL1999/000217 WO1999055306A1 (en) 1998-04-27 1999-04-23 Pharmaceutical composition comprising factor viii and neutral liposomes

Publications (3)

Publication Number Publication Date
JP2002512947A JP2002512947A (ja) 2002-05-08
JP2002512947A5 true JP2002512947A5 (enExample) 2006-01-05
JP4545928B2 JP4545928B2 (ja) 2010-09-15

Family

ID=11071435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000545506A Expired - Fee Related JP4545928B2 (ja) 1998-04-27 1999-04-23 第viii因子及び中性リポソームを含有する薬学的組成物

Country Status (12)

Country Link
US (2) US6593294B1 (enExample)
EP (1) EP1079805B1 (enExample)
JP (1) JP4545928B2 (enExample)
AT (1) ATE283034T1 (enExample)
AU (1) AU747391B2 (enExample)
BR (1) BR9909978A (enExample)
CA (1) CA2329768C (enExample)
DE (1) DE69922189T2 (enExample)
ES (1) ES2233036T3 (enExample)
MX (1) MXPA00010241A (enExample)
PT (1) PT1079805E (enExample)
WO (1) WO1999055306A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625584B2 (en) * 2000-11-30 2009-12-01 The Research Foundation Of State University Of New York Method of complexing a protein by the use of a dispersed system and proteins thereof
US20020132982A1 (en) * 2000-11-30 2002-09-19 Balasubramanian Sathyamangalam V. AHF associated dispersion system and method for preparation
US8110218B2 (en) 2000-11-30 2012-02-07 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein-lipid complexes
US7718160B2 (en) * 2002-07-02 2010-05-18 The Board Of Regents Of The University Of Texas System Radiolabeled compounds and liposomes and their method of making and using same
US7351688B2 (en) * 2003-02-05 2008-04-01 The Research Foundation Of State University Of New York Compositions and methods for less immunogenic protein formulations
DE602004013769D1 (de) * 2003-04-15 2008-06-26 Opperbas Holding Bv Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel
US20050069578A1 (en) * 2003-08-05 2005-03-31 Balasubramanian Sathyamangalam V. Reconstitution medium for protein and peptide formulations
US20070003607A1 (en) * 2003-09-02 2007-01-04 Vibhudutta Awasthi Neutral liposome-encapsulated compounds and methods of making and using thereof
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
JP4966018B2 (ja) * 2004-01-23 2012-07-04 カムルス エービー 三元非ラメラ脂質組成物
SI1824988T1 (sl) 2004-11-12 2017-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
US8895717B2 (en) * 2005-04-15 2014-11-25 The Board Of Regents Of The University Of Texas System Delivery of siRNA by neutral lipid compositions
JP2008544990A (ja) * 2005-06-29 2008-12-11 ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク 低免疫原性蛋白質−脂質複合体に関する組成物および方法
WO2007021822A2 (en) 2005-08-09 2007-02-22 The Research Foundation Of State Of University Of New York At Buffalo Compositions and methods of preparation of liposomal microparticulate il-12
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007117469A2 (en) 2006-03-30 2007-10-18 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
US7875288B2 (en) 2006-03-30 2011-01-25 The Research Foundation Of State University Of New York Method for treating blood coagulation disorders
CN105838699A (zh) * 2006-12-15 2016-08-10 巴克斯艾尔塔公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
EP3231440A1 (en) 2006-12-22 2017-10-18 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
CN103739712B (zh) 2008-06-24 2016-10-05 德国杰特贝林生物制品有限公司 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
PL2299953T3 (pl) 2008-07-14 2017-10-31 Polypid Ltd Kompozycja nośnika leku o przedłużonym uwalnianiu
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
IN2012DN00570A (enExample) 2009-07-14 2015-06-12 Polypid Ltd
US10058837B2 (en) 2009-08-28 2018-08-28 The Trustees Of Columbia University In The City Of New York Systems, methods, and devices for production of gas-filled microbubbles
WO2011084610A1 (en) 2009-12-16 2011-07-14 Children Medical Center Corporation Liposomes for preventing the spread of hiv
EP2512588A4 (en) 2009-12-16 2014-06-04 Univ Columbia METHODS, DEVICES AND SYSTEMS FOR ULTRASOUND-RELEASED ON-DEMAND AGGREGATE FREEZING
AU2011208374B2 (en) 2010-01-19 2016-09-08 Polypid Ltd. Sustained-release nucleic acid matrix compositions
US8637448B2 (en) 2010-09-14 2014-01-28 University Of Rochester Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface
DE102010043733A1 (de) 2010-11-10 2012-05-10 Oxprotect Gmbh Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen
ES2651523T3 (es) 2012-02-15 2018-01-26 Csl Behring Gmbh Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
AU2015283822B2 (en) 2014-07-02 2019-10-03 CSL Behring Lengnau AG Modified von willebrand factor
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
DK3265483T3 (da) 2015-03-06 2020-03-02 CSL Behring Lengnau AG Modificeret von Willebrand-faktor med forbedret halveringstid
SG11201708755WA (en) 2015-05-22 2017-12-28 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
CN107810194B (zh) 2015-05-22 2021-10-08 康诺贝林伦瑙有限公司 用于制备经修饰的血管性血友病因子的方法
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
SG10201912857XA (en) 2016-01-07 2020-02-27 CSL Behring Lengnau AG Mutated von willebrand factor
SG11201805497QA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated truncated von willebrand factor
WO2017220099A1 (en) 2016-06-24 2017-12-28 Statens Serum Institut Adjuvants with modified drainage properties
US11246832B2 (en) * 2016-06-28 2022-02-15 Verily Life Sciences Llc Serial filtration to generate small cholesterol-containing liposomes
AU2017358865A1 (en) 2016-11-11 2019-05-09 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
TW201828975A (zh) 2016-11-11 2018-08-16 瑞士商Csl貝林重組技能公司 用於治療血友病之截短型類血友病因子(von Willebrand factor)多肽類

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7900459A (nl) 1979-01-19 1980-07-22 Hendrik Coenraad Hemker Prof D Farmaceutisch preparaat en werkwijze ter bereiding daarvan.
JPS56127307A (en) * 1980-03-11 1981-10-06 Green Cross Corp:The Blood-coagulation factor 8 pharmaceutical for oral administration
US4348384A (en) 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
AU7217891A (en) * 1990-02-13 1991-09-03 Oxford Virology Plc Therapeutic agents, and intermediates for the synthesis thereof
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method

Similar Documents

Publication Publication Date Title
JP2002512947A5 (enExample)
JP4545928B2 (ja) 第viii因子及び中性リポソームを含有する薬学的組成物
AU692460B2 (en) Bioadhesive emulsion preparations for enhanced drug delivery
CA2784394C (en) Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
Rogers et al. The potential of liposomes in oral drug delivery
JP4728580B2 (ja) 製剤
JP2022101576A (ja) スギ花粉エピトープを封入するtimp(組織性メタロプロテアーゼ阻害因子)
US8377885B2 (en) Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP0460100A1 (en) Liposome gel composition and method
KR20010021911A (ko) 구강내에서의 약제의 제어방출용 탄닌산-중합체 조성물
Torchilin Affinity liposomes in vivo: factors influencing target accumulation
JP2001513544A (ja) 脂質含有組成物及びこれらの使用
Ong et al. Nanoparticular and other carriers to deliver lactoferrin for antimicrobial, antibiofilm and bone-regenerating effects: a review
JPH11507628A (ja) 改良されたリポソーム製剤
JP2010518012A (ja) カンプトテシン誘導体を含む医薬組成物
JP3926626B2 (ja) 免疫学的寛容−誘導物質
Malmsten Block copolymers in pharmaceutics
Kenny et al. Proteins of the kidney microvillar membrane. Reconstitution of endopeptidase in liposomes shows that it is a short-stalked protein
Bergers et al. Interleukin-2-containing liposomes: interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines
Rogachev et al. Permeation of nanoparticles into pulmonary surfactant monolayer: in situ X-ray standing wave studies
JP2005529086A (ja) 精製大豆ホスファチジルセリンによって作製される渦巻状物
CN1774281B (zh) 包含蛋白质和/或多肽以及胶体颗粒的药物组合物
JPWO2003015753A1 (ja) リポソーム製剤
USRE49251E1 (en) Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
JP2817883B2 (ja) 高度に完全なリポソームおよびその製剤法と用途